1. Signaling Pathways
  2. Autophagy
  3. Atg4


Autophagy-related 4

Atg4 is the sole cysteine protease among dozens of Atg proteins and functions as an essential factor in the Atg8 conjugation system. While only one Atg4 is present in yeast, there are four Atg4 homologues (Atg4A, Atg4B, Atg4C, and Atg4D) in human and in mouse with different substrate specificities and catalytic efficiencies. Atg4 cleaves Atg8 at the peptide bond on the glycine residue at the C-terminus, thus allowing the conjugation of Atg8 to phosphatidylethanolamine (PE) with the participation of other autophagy molecules. Atg4 can also serve as a deconjugating enzyme, which cleaves the amide bond of the conjugated Atg8 and releases it from the autophagosomal membrane. The latter step is important for reusing Atg8 upon autophagy completion. Moreover, this deconjugation process may also occur on isolation membrane, which would positively or negatively affect membrane formation.

Atg4 Related Products (5):

Cat. No. Product Name Effect Purity
  • HY-125169
    NSC 185058
    Inhibitor 99.52%
    NSC 185058 is an inhibitor of ATG4B, a major cysteine protease. Inhibition of ATG4B using NSC 185058 markedly attenuates autophagic activity.
  • HY-112818
    S130 is a high affinity, selective inhibitor of ATG4B (a major cysteine protease) with an IC50 of 3.24 µM. S130 suppresses autophagy flux.
  • HY-112711
    LV-320 is a potent and uncompetitive ATG4B inhibitor with an IC50 of 24.5 µM and a Kd of 16 µM. LV-320 inhibits ATG4B enzymatic activity, blocks autophagic flux in cells, and is stable, non-toxic and active in vivo.
  • HY-W287569
    STK683963 is a strong activator of cellular ATG4B activity. STK683963 can act as a mediator of redox-regulation of ATG4B in cells. STK683963 can be used for the research of cancer.
  • HY-144636
    Atg4B-IN-2 is a potent competitive Atg4B inhibitor with Ki value of 3.1 μM, also possesses declining PLA2 inhibitory potency, IC50s of 11 μM and 3.5 μM for Atg4B and PLA2, respectively. Atg4B-IN-2 enhances the anticancer activity of anti-castration-resistant prostate cancer agents via autophagy inhibition.